GUILLERMO GARCIA-MANERO to Valproic Acid
This is a "connection" page, showing publications GUILLERMO GARCIA-MANERO has written about Valproic Acid.
Connection Strength
1.576
-
Therapy for older patients with acute myeloblastic leukemia: a problem in search of a solution. Leuk Lymphoma. 2012 Jun; 53(6):1013-4.
Score: 0.382
-
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007 Oct 01; 110(7):2302-8.
Score: 0.271
-
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9.
Score: 0.255
-
Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res. 2005 Jul; 29(7):739-48.
Score: 0.230
-
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15; 121(4):556-61.
Score: 0.113
-
Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol. 2011 Feb; 86(2):237-8.
Score: 0.087
-
Demethylating agents in myeloid malignancies. Curr Opin Oncol. 2008 Nov; 20(6):705-10.
Score: 0.074
-
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res. 2008 Oct 01; 14(19):6296-301.
Score: 0.074
-
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood. 2006 Aug 15; 108(4):1174-82.
Score: 0.063
-
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014 Mar; 73(3):495-501.
Score: 0.027